Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids

Executive Summary

FDA's complete response letter includes extensive list of new studies needed to support abuse-deterrence claims not featured in two prior CRLs, Pain Therapeutics says, wondering why the agency is only now raising issues that could have been discussed previously.

Advertisement

Related Content

FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
US FDA Review Management Challenged After Spate Of Complete Response Letters
FDA’s Promotional Enforcement Still Playing It Safe
Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
FDA's Drug Promotion Advisory Reviews Taking Longer
KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Pain's Remoxy Skips Over Panel On Rocky Road To Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register